Physician profile
Amie Seitz
NPI 1861032203
$1,355.41
in general payments reported to CMS, 2019-2025
24 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.97 · 2022: $205 · 2023: $331 · 2024: $630 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Education: $19.43 · Entertainment: $14.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.96 |
| Education | $19.43 |
| Entertainment | $14.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $222.12 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Abbvie INC. | $171.77 | 2021-2024 | |
| Pfizer INC. | $138.22 | 2023-2025 | |
| Lilly USA, LLC | $121.25 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $72.87 | 2022-2024 | Airsupra |
| Amgen INC. | $70.93 | 2022-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $60.85 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $51.72 | 2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $49.07 | 2025 | Omnipod |
| Esperion Therapeutics, INC. | $46.67 | 2023-2024 | Nexletol |
| Amneal Pharmaceuticals LLC | $45.01 | 2024-2025 | Unithroid |
| Currax Pharmaceuticals LLC | $40.44 | 2023 | Contrave, Nexletol, Nexlizet |
| Novo Nordisk INC | $36.55 | 2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.24 | 2023-2024 | Jardiance |
| Eisai INC. | $31.49 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $23.58 | 2023 | Urolift |
| Otto Bock Healthcare LP | $19.43 | 2024 | |
| Medtronic, INC. | $19.28 | 2024 | Minimed 780g |
| Merck Sharp & Dohme LLC | $19.15 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $18.87 | 2023 | Trelegy Ellipta |
| Viiv Healthcare Company | $18.27 | 2025 | Apretude |
| Lucid Diagnostics INC. | $14.67 | 2023 | |
| Optos, INC. | $14.62 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Phathom Pharmaceuticals, INC. | $14.34 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amie Seitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.